KLK6-IN-1

KLK6-IN-1 (compound 42) noncompetitively and reversibly inhibits purified KLK6 with an IC₅₀ of 1.57 μM and a K_i of 0.8 μM, while competitively and reversibly inhibiting purified plasmin and KLK1 with IC₅₀ values of 7.4 μM (K_i = 1.3 μM) and 5.1 μM (K_i = 2.4 μM), respectively^[1].
KLK6-IN-1 (10 μM; 15 min preincubation, enzymatic reaction at 37 °C) displays high selectivity for KLK6, KLK1, and plasmin, with minimal inhibition of most tested CNS-related proteases^[1].
KLK6-IN-1 (10-100 μM; 24 h) is noncytotoxic to both primary mouse cortical and striatal neurons at concentrations up to 25 μM, and exhibits only mild cytotoxicity at 50 μM and above^[1].
KLK6-IN-1 (5 μM; 4 days) significantly promotes the differentiation of both CG4 and primary rat oligodendrocyte precursor cells into mature oligodendrocytes^[1].
KLK6-IN-1 (0.5-1.5 μM; 24 h, combined with 10 ng/mL LPS) significantly reduces LPS-induced IL-1β and TNFα secretion from primary rat microglial cultures after 24 h of treatment^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.